NeuroSense Therapeutics Ltd. (NRSN)

Pharmaceutical Preparations · market cap $13M · as of 2026-07-17

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-12-01

NDA Filing

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

NeuroSense Therapeutics Ltd. (NRSN) is a micro-cap clinical-stage pharmaceutical company with 17 employees and a market cap of approximately $28M at ~$0.70/share. Its pipeline centers on PrimeC, a fixed-dose combination asset in Phase 2 for Alzheimer's Disease, and a separate fixed-dose combination of Ciprofloxacin/Celecoxib in Phase 2 for ALS. No near-term catalysts are currently calendared.

The catalyst path

2026-12-01NDA Filingimp 6/10
2026-12-31NDA Filingimp 6/10

Pipeline

Asset	Phase	Indication
PrimeC	Phase 2	Alzheimer Disease

Price & technical context

3-month

-75.3%

6-month

-85.4%

12-month

-90.0%

52-wk range

$2.33–$24.80

vs 50-day MA

-58.8%

vs 200-day MA

-82.0%

Realized vol

93.9%

Max drawdown

-90.7%

Daily closes through 2026-10-27. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for NRSN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.